Zimbabwe has rejected a major US health deal valued at $367m (£272m) over five years because of Washington's insistence on confidential information.
This rejection came to light following a internal memorandum dated December was leaked, indicating that Head of State Emmerson Mnangagwa felt the agreement was "skewed".
An official spokesman has since stated that the US was demanding access to genetic material for scientific study and commercial gain but was unwilling to guarantee the benefits from future vaccines.
"We will now turn to the difficult and regrettable task of ending our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had furnished more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for continued dialogue to secure a agreement acceptable to both sides so the country's vital HIV treatment initiative can proceed.
Broader Context
This development comes after a comparable situation in neighbouring Kenya, where a court blocked a related health funding agreement following concerns were filed about the safety of citizens' medical information.
After returning to office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump stated its expenditure was "wasteful" and his administration was seeking direct bilateral deals to enhance openness and accountability.
As per statements, Sixteen African countries have so far agreed to similar agreements, constituting over $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration would have delivered significant advantages for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through American-funded initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its biological resources and data indefinitely, without any corresponding assurance of access to any medical innovations – like new medicines or tests – that might be developed from that provided information," he stated.
"Put simply, our country would supply the basic resources for scientific discovery with no certainty that the final treatments would be accessible to our population should a future disease outbreak arise."
National Interest and Global Health
Mangwana further noted that the American exit from the global health body and its push of bilateral deals were undermining systems previously set up via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to deal with potential pandemics.
"This framework is intended to ensure that when a nation provides its information, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
These objections regarding the US deal "are not meant as hostility towards the US," he added.
"We encourage continued discussions with our American counterparts on how future co-operation could be structured in a manner that respects the sovereignty and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the government's concerns, but urged that negotiations need to persist considering a large portion of the country's HIV programmes relied on external financing.
"If specific concerns exist, such as those relating to data governance or implementation frameworks, these can frequently be resolved via detailed discussion and mutually agreed protections," the group said.
This impasse emphasises the continuing challenges between receiving crucial foreign assistance and protecting local interests in an increasingly data-driven world.